134 related articles for article (PubMed ID: 24751319)
41. A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes.
Venkatasubramanian R; Kumar CN; Pandey RS
J Affect Disord; 2013 Sep; 150(2):644-8. PubMed ID: 23507369
[TBL] [Abstract][Full Text] [Related]
42. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
[TBL] [Abstract][Full Text] [Related]
43. [Changes and Prediction of Social Functional Disability and Quality of Life in Patients with Major Depressive Disorder over the Course of 1-Year Medication].
Wang JY; Yuan ML; Zhang W
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):904-910. PubMed ID: 36224695
[TBL] [Abstract][Full Text] [Related]
44. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
45. Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder.
Dong L; Xu L; Li Y; Lv Y; Liu H; Li Y; Xu F; Wu J; Zheng Q; Li L
J Affect Disord; 2018 Mar; 229():224-230. PubMed ID: 29324370
[TBL] [Abstract][Full Text] [Related]
46. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
Snedecor SJ; Botteman MF; Schaefer K; Sarocco P; Barry N; Pickard AS
J Ment Health Policy Econ; 2010 Mar; 13(1):27-35. PubMed ID: 20571180
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC
CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807
[TBL] [Abstract][Full Text] [Related]
48. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder.
Sonawalla SB; Papakostas GI; Petersen TJ; Yeung AS; Smith MM; Sickinger AH; Gordon J; Israel JA; Tedlow JR; Lamon-Fava S; Fava M
Psychosomatics; 2002; 43(4):310-6. PubMed ID: 12189257
[TBL] [Abstract][Full Text] [Related]
49. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
50. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA
Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066
[TBL] [Abstract][Full Text] [Related]
51. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
[TBL] [Abstract][Full Text] [Related]
52. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
[TBL] [Abstract][Full Text] [Related]
53. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
Benazzi F; Berk M; Frye MA; Wang W; Barraco A; Tohen M
J Clin Psychiatry; 2009 Oct; 70(10):1424-31. PubMed ID: 19906346
[TBL] [Abstract][Full Text] [Related]
54. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder.
Freeman MP; Hock RS; Papakostas GI; Judge H; Cusin C; Mathew SJ; Sanacora G; Iosifescu DV; DeBattista C; Trivedi MH; Fava M
J Clin Psychopharmacol; 2020; 40(3):287-292. PubMed ID: 32332464
[TBL] [Abstract][Full Text] [Related]
55. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
Sheehan DV; Rozova A; Gossen ER; Gibertini M
Psychopharmacol Bull; 2009; 42(4):5-22. PubMed ID: 20581790
[TBL] [Abstract][Full Text] [Related]
56. A meta-analysis of the efficacy of venlafaxine extended release 75-225 mg/day for the treatment of major depressive disorder.
Thase M; Asami Y; Wajsbrot D; Dorries K; Boucher M; Pappadopulos E
Curr Med Res Opin; 2017 Feb; 33(2):317-326. PubMed ID: 27794623
[TBL] [Abstract][Full Text] [Related]
57. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Luo YL; Zhang MY; Wu WY; Li CB; Lu Z; Li QW
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1522-5. PubMed ID: 19733606
[TBL] [Abstract][Full Text] [Related]
58. Fluoxetine in medically stable, depressed geriatric patients: effects on weight.
Goldstein DJ; Hamilton SH; Masica DN; Beasley CM
J Clin Psychopharmacol; 1997 Oct; 17(5):365-9. PubMed ID: 9315987
[TBL] [Abstract][Full Text] [Related]
59. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine.
Lam RW; Endicott J; Hsu MA; Fayyad R; Guico-Pabia C; Boucher M
Int Clin Psychopharmacol; 2014 Sep; 29(5):239-51. PubMed ID: 24583567
[TBL] [Abstract][Full Text] [Related]
60. The Relationship between Symptom Relief and Psychosocial Functional Improvement during Acute Electroconvulsive Therapy for Patients with Major Depressive Disorder.
Lin CH; Yang WC
Int J Neuropsychopharmacol; 2017 Jul; 20(7):538-545. PubMed ID: 28430980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
